Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28634310 | 0.91 | MCL1 (0.57) | MCL1L3MBTL1LMNATSHRFFAR1 | |
| SCHEMBL13490816 | 0.90 | FFAR1 (0.54) | MCL1FFAR1FFAR4PLA2G2APPARG | |
| SCHEMBL12051638 | 0.85 | RXRA (0.47) | FFAR1FFAR4 | |
| SCHEMBL13008060 | 0.83 | MAPT (0.47) | LMNATSHRPPARGPPARAGAA | |
| SCHEMBL10207287 | 0.82 | LMNA (0.63) | L3MBTL1LMNAFFAR1FFAR4PLA2G4B | |
| SCHEMBL2280556 | 0.78 | TSHR (0.57) | MCL1L3MBTL1TSHRFFAR1FFAR4 | |
| SCHEMBL10207303 | 0.77 | LMNA (0.61) | L3MBTL1LMNAFFAR1PLA2G4BPPARA | |
| SCHEMBL24340853 | 0.76 | MAPT (0.50) | MCL1L3MBTL1LMNATSHRFFAR1 | |
| SCHEMBL10290140 | 0.76 | PLA2G4B (0.59) | L3MBTL1LMNAFFAR1PLA2G4BPPARA | |
| SCHEMBL8088521 | 0.76 | PLA2G4B (0.59) | L3MBTL1LMNAFFAR1PLA2G4BPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | TOMM34, TOMM70, TOMM40 | MCL1 24/4885L3MBTL1 1175/4885LMNA 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.